One report showed that treatment with the DNA hypomethylating agent (HMA), decitabine (DAC), leads to increased CD8+ T cell tumor infiltration and inhibits tumor growth via CD8+ T cell-dependent activity in different mouse tumor models [113]. This evidence concerns the gene CD8A and neoplasm.